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“I am among those who think that science has great beauty” 





Hedgehog signaling is crucial for diverse aspects of animal development, essential in regulating many 
cellular processes and is largely implicated in various forms of human cancer. However, many aspects of 
Hedgehog signaling are not completely understood. This thesis aims to contribute towards a better 
understanding of the mechanisms acting on Hedgehog-GLI signaling and explore their possible therapeutic 
potential. 
PAPER I. We demonstrate that the small molecule RITA, a p53 activator, downregulates Hedgehog 
signaling in human medulloblastoma and rhabdomyosarcoma cells via JNK kinase and irrespective of p53. 
In vitro RITA enhanced the anti-proliferative effects of the GLI antagonist GANT61. RITA was more 
potent than GANT61 in downregulating Hedgehog-GLI signaling in rhabdomyosarcoma subcutaneous 
xenograft tumors with the dual drug administration almost completely blocking the Hedgehog signaling 
response in vivo, suggesting a certain antagonism of the two drugs. Notably, RITA and GANT61 co-
administration decreased cell proliferation and elicited a broader response of pathways involved in cancer 
cell growth, providing a plausible interpretation for tumor reduction in the absence of Hedgehog signaling 
downregulation. 
PAPER II. We address the possible therapeutic role of Hedgehog-GLI1 signaling for targeting and 
prognosis of ER-alpha positive breast cancer. We showed that expression of the Hedgehog signaling 
effector protein GLI1 is higher in tamoxifen resistant relative to tamoxifen sensitive cells. In both cell types 
GLI1 depletion mitigated cell proliferation and ER-alpha activity, irrespective of estrogen stimulation. 
Tamoxifen cytotoxicity was enhanced by GANT61 co-treatment, both in tamoxifen resistant and sensitive 
breast cancer cells, reflecting a crosstalk between ER-alpha and Hedgehog-GLI1 signaling. We have 
observed a positive correlation between GLI1 and ER-alpha/ER-alpha target gene expression, while high 
GLI1 expression was associated with poor distant metastasis-free survival in breast cancer patients. 
PAPER III. We identified a signature of GLI1 target genes via a combination of RNA-seq analyses of 
GLI1 overexpression and depletion datasets supplemented with in-depth validation in human cancer cell 
lines. Additionally, we found that RNA editing of GLI1 can modulate its effects on GLI1 target genes. 
Markedly, one of the highly upregulated targets, FOXS1, was found to engage in feedback mechanisms 
limiting the capacity of GLI1 to act as a proliferation factor in medulloblastoma and rhabdomyosarcoma 
cells. FOXS1 was both highly expressed and positively correlated with GLI1 in SHH medulloblastoma, 
further arguing for the existence of a FOXS1-GLI1 interplay in human tumors. 
PAPER IV (Manuscript). In this ongoing work we address the role of circRNAs in the context of 
Hedgehog signaling activation and Hedgehog-linked SHH medulloblastoma tumors. Via modified RNA-
seq protocols we have determined the circRNA transcriptome of Daoy medulloblastoma and human 
embryonic palatal mesenchyme HEPM cells, following activation of Hedgehog pathway with SHH ligand 
or Smoothened agonist SAG. In total, 29 selected circRNAs were independently validated by Sanger 
sequencing and RT-PCR assays. Of these circRNAs, 10 were apparently regulated by Hedgehog signaling 
activation, however to a much lesser extent compared with known target genes of the pathway, e.g. GLI1 
and HHIP. 7 circRNAs had reduced expression in human medulloblastoma tumors in comparison to 
normal cerebellum, while the linear mRNAs originating from the same genes did not exhibit a reduced 
expression. These findings highlight distinct regulatory mechanisms acting on the BACH1, CDYL, 
FKBP8, GLIS1, OGDH, SMARCA5 and ZKSCAN1 circRNAs and deserve further analysis for possible 
contribution to the development of medulloblastoma. 
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1 Introduction 
1.1 Hedgehog signaling pathway 
Hedgehog pathway is a highly conserved signal transduction cascade, initially discovered in 
Drosophila melanogaster (Nusslein-Volhard and Wieschaus, 1980) and subsequently 
described in higher organisms, including humans (Ingham and McMahon, 2001). The 
Hedgehog signaling pathway plays a pivotal role in embryogenesis, embryonic stem cell 
differentiation and tissue patterning. Later in adult physiology, the pathway is involved in 
stem cell maintenance, tissue repair and regeneration. Disruption of Hedgehog signaling leads 
to a variety of developmental abnormalities affecting multiple organ systems (Briscoe and 
Therond, 2013; Teglund and Toftgård, 2010), including holoprosencephaly (Gorlin, 1995), 
polydactyly, craniofacial defects and skeletal malformations (Ingham and McMahon, 2001; 
Jiang and Hui, 2008), whereas its aberrant ectopic activation can lead to tumor formation. 
1.1.1 Hedgehog ligands 
In mammals, canonical Hedgehog signaling is initiated by one of the three extracellular 
Hedgehog glycoprotein ligands, i.e Sonic Hedgehog (SHH), Indian Hedgehog (IHH) and 
Desert Hedgehog (DHH), which are expressed in tissue-specific manner. (Ingham, 2008; 
Pathi et al., 2001; Teglund and Toftgård, 2010). SHH has been the most studied of the three, 
as it is broadly expressed and affects the development of many organs, including central 
nervous system, lungs, teeth, intestines and hair follicles (Altaba et al., 2002; Chiang et al., 
1996). IHH is involved in the cartilage, bone, intestine and ovary formation, while DHH 
regulates germ cell development in testis (Briscoe and Therond, 2013; McMahon et al., 2003; 
Varjosalo and Taipale, 2008). 
All Hedgehog ligands are synthesized as precursor proteins that undergo autocatalytic 
cleavage and a release of amino-terminal domain containing a signaling peptide (Porter et al., 
1995). This results in subsequent modifications of the amino-terminal domain: the covalent 
attachment of cholesterol moiety to its carboxyl terminus and palmitoylation of its amino 
terminus, which are required for proper activity, secretion, movement and reception of the 
Hedgehog ligands (Chen et al., 2004; Ingham and McMahon, 2001; Lewis et al., 2001; 
Pepinsky et al., 1998). The Hedgehog ligands are secreted as signaling molecules, which 
function both in nearby and distant cells (Varjosalo and Taipale, 2008). 
1.1.2 Hedgehog signaling transduction from cell membrane to GLI 
Mammalian Hedgehog signaling depends on primary cilium, a specialized cellular 
compartment where many of Hedgehog signaling components co-localize (Haycraft et al., 
2005). The main pathway components are the 12-span transmembrane receptor Patched 
(PTCH1, PTCH2), which in the absence of Hedgehog ligands represses the proto-oncogene 
Smoothened (SMO), thus preventing the downstream signaling. In the “OFF” state 
Suppressor of fused (SUFU) binds and sequesters Glioma-associated oncogene family of 
transcription factors (GLI1, GLI2, GLI3), restraining target gene transcription (Figure 1). 
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At the cell membrane, Hedgehog ligands can directly interact with PTCH, which in unbound 
state generally is localized at the base of the cilium. Of two PTCH homologs, PTCH1 is 
expressed ubiquitously, whereas PTCH2 is preferentially expressed in skin and testis 
(Carpenter et al., 1998; Hahn et al., 1996a). In addition, Hedgehog ligands can bind to 
membrane co-receptors CAM-related/downregulated by oncogenes (CDO), Brother of CDO 
(BOC) and Growth arrest-specific 1 (GAS1), which depending on the tissue context, usually 
enhance binding of the Hedgehog ligands to PTCH, and cooperate in promotion of Hedgehog 
signaling (Allen et al., 2011; Cardozo et al., 2014; Izzi et al., 2011). Another co-receptor, 
Hedgehog interacting protein (HHIP) acts as a negative regulator by competing for Hedgehog 
ligand binding with PTCH (Beachy et al., 2010). 
Binding of extracellular Hedgehog ligands to PTCH results in internalization and endosomal 
degradation of PTCH-ligand complex, releasing the inhibitory effects of PTCH on SMO, a G 
protein-coupled receptor protein (Murone et al., 1999). It is not yet fully clear how PTCH 
regulates SMO activity. However, current view suggests that PTCH does not physically 
interact with SMO, but given its similarity to bacterial proton-driven efflux pumps, may 
rather function as a transporter of various SMO-regulating small molecules across the 
cytoplasmic membrane (Hasanovic et al., 2018; Taipale et al., 2002). In line with this, 
naturally occurring molecules that can be transported by PTCH, such as oxysterols and 
phosphatidylinositol 4-phosphate were shown to activate, while vitamin D3 was suggested to 
repress SMO activity (Bijlsma et al., 2006; Corcoran and Scott, 2006; Yavari et al., 2010). 
Figure 1. A simplified schematic model of the Hedgehog pathway in vertebrates.
(Left panel) In the absence of Hedgehog ligands (HH), PTCH represses SMO activity keeping the intracellular signal
transduction at the “OFF” state. Here, full-length GLI proteins undergo sequential phosphorylation and proteolytic
truncation, processing into repressor forms (GLI-R), predominantly GLI3. (Right panel) Binding of HH results in
loss of PTCH activity, consequent activation and relocation of SMO from intracellular vesicles to cilium, and finally,
recruitment and activation of full-length GLI proteins. Cytoplasmic sequestration of GLI by SUFU is released.
Activated full-length GLI proteins (GLI-A), predominantly GLI1 and GLI2, enter the nucleus and promote
transcription of target genes.
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Activation of SMO also depends on phosphorylation by G protein-coupled receptor kinase 2 
(Teglund and Toftgård, 2010). 
In response to Hedgehog signaling in vertebrates, SMO shuttles from intracellular vesicles to 
the membrane of the primary cilium, resulting in recruitment and activation of the GLI 
transcription factors (Haycraft et al., 2005). Here, several proteins, including SUFU, KIF7, 
regulate GLI function (Teglund and Toftgård, 2010). In the absence of Hedgehog signaling, 
SUFU makes an inactive complex with GLI, preventing its translocation into nucleus, while 
activated SMO causes disassociation of SUFU-GLI complex within the primary cilia. Upon 
activation, GLI factors translocate to the nucleus and promote transcription of Hedgehog 
target genes, including GLI1 itself, PTCH and HHIP (Briscoe and Therond, 2013; Haycraft et 
al., 2005; Ingham, 2008; Kasper et al., 2006) (Figure 1). PTCH and HHIP provide a negative 
feedback loop restricting both auto- and paracrine spreading of the Hedgehog ligands, while 
GLI1 acts as an ultimate amplifier of the initial Hedgehog signal. 
Additional targets of the Hedgehog-GLI pathway include FOXA2, which in turn induces the 
SHH activity and is involved in neural development (Mavromatakis et al., 2011); cyclin D1 
and MYCN, involved in cell-cycle progression and regulation; BCL2, which can be increased 
upon Hedgehog signaling activation and is involved in cell survival; SNAIL, Insulin-like 
growth factor (IGF2) and Vascular endothelial growth factor (VEGF), involved in epithelial-
mesenchymal transition in cancer metastasis (Amakye et al., 2013; Everson et al., 2018; Pak 
and Segal, 2016; Varjosalo and Taipale, 2008). The broad spectrum of genes that are 
regulated by Hedgehog signaling is continuously being discovered. In this perspective, in 
PAPER III, we have identified new GLI1 target genes using a combination of RNA-seq and 
follow-up molecular validation techniques in human cancer cell lines. 
1.1.3 The GLI transcription factors 
The GLI proteins contain five Zinc-finger motifs of which Zinc-finger 4 and 5 bind to a 9 
base pair DNA binding consensus sequence 5’-GACCACCCA within the GLI target genes 
(Kinzler and Vogelstein, 1990). GLI1 was the first known GLI factor, initially identified in 
glioblastoma (Kinzler et al., 1987). GLI1 acts as an activator of the pathway and is found 
only in a full-length activator form, while GLI2 and GLI3 can also be partially processed into 
truncated repressor forms (Aberger and Ruiz, 2014; Teglund and Toftgård, 2010; Yang et al., 
2010). GLI1 is considered as a main effector of Hedgehog signaling which is capable of 
upregulating its own gene expression, resulting in a positive feedback loop (Briscoe and 
Therond, 2013). Thus, expression of GLI1 is a reliable indicator of Hedgehog pathway 
activity (Shimokawa et al., 2008). 
Some studies argue for a prominent role of GLI2 in Hedgehog signaling activation and 
subsequent tumor formation, which unlike GLI1, could be triggered independent of SHH 
(Bai et al., 2002; Bai and Joyner, 2001; Park et al., 2000). Moreover, transgenic mice bearing 
homozygous Gli1 hypomorphic or null mutations were shown to be phenotypically normal, 
while mice with similar mutations in Gli2 died soon after birth having abnormalities in 
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various tissues, including spinal cord and lungs (Bai and Joyner, 2001; Park et al., 2000). 
Interestingly, Gli1 and Gli2 double homozygous null mutants have more severe 
developmental defects, suggesting their overlapping roles (Bai et al., 2002; Bai and Joyner, 
2001; Park et al., 2000). Several studies also indicate certain compensatory roles of GLI1 and 
GLI2 functions (Bai and Joyner, 2001; Kimura et al., 2005; Lipinski et al., 2006). For 
example, when Gli1 cDNA was knocked into the Gli2 locus, it was able to rescue all Shh 
signaling defects in Gli2-/- mice (Bai and Joyner, 2001). It is noteworthy that, although these 
gene misexpression studies can greatly clarify the functions of GLI proteins, they may not 
necessarily fully reflect the normal developmental situations. 
Regulation of the GLI factors involves a multitude of mechanisms including post-
transcriptional modifications, such as alternative splicing (Shimokawa et al., 2008), RNA 
editing (Shimokawa et al., 2013), post-translational modifications including acetylation, 
phosphorylation, ubiquitination, and cytoplasmic-nuclear shuttling (Briscoe and Therond, 
2013; Mirza et al., 2019). For example, in the absence of Hedgehog ligand, full length GLI 
proteins (mainly GLI3) are phosphorylated by Protein kinase A (PKA), Glycogen synthase 
kinase 3-beta (GSK3-β), Casein kinase 1 (CK1), leading to proteolytic cleavage of GLI into 
carboxy-terminally truncated repressor form (Teglund and Toftgård, 2010; Yang et al., 2010). 
It has been shown that GLI1 can be RNA-edited by Adenosine deaminase acting on RNA 
(ADAR) via deamination of the Adenosine at nucleotide position 2179, converting it to 
Inosine. This Adenosine to Inosine substitution of the mRNA molecule results in a codon 
change from Arginine to Glycine at position 701 of the GLI1 protein, resulting in subsequent 
changes in its functional activity. As a result, edited GLI1 can exhibit reduced sensitivity 
towards SUFU, slightly higher transcriptional activity, but reduced effectivity at promoting 
cellular growth (Shimokawa et al., 2013). It is worth noting, that we have further addressed 
the cell-context specific differences or similarities of GLI1 and edited GLI1 target genes in 
PAPER III. 
1.1.4 Regulation of Hedgehog pathway by non-Hedgehog signals 
The Hedgehog pathway can also be activated by so-called “non-canonical” mechanisms, 
which are Hedgehog ligand-independent. This mode of activation is downstream of 
PTCH/SMO and culminates in the activation of the GLI transcription factors. 
Several signaling cascades that can promote tumorigenesis, e.g. Transforming growth factor 
beta (TGF-beta), Epidermal growth factor receptor (EGFR), Mitogen-activated kinases 
(MAPK), K-RAS, PI3K/AKT/mTOR, Wingless (WNT) pathways were shown to converge 
and activate Hedgehog signaling. Additionally, crosstalk between Hedgehog signaling 
components and tumor suppressors, such as p53, PTEN, PCAF have also been demonstrated 
(Aberger and Ruiz, 2014; Mazza et al., 2013; Stecca and Ruiz i Altaba, 2009) (Figure 2). 
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1.1.4.1 JNK kinase mediated regulation of Hedgehog-GLI 
JUN amino-terminal kinases (JNK1, JNK2, JNK3), also known as stress-activated protein 
kinases (SAPK), are components of the major group of MAPK (Coffey, 2014). JNKs are 
activated by dual phosphorylation on Threonine and Tyrosine in the conserved tripeptide 
motif by the members of MAPK kinase group of protein kinases. Upon activation, JNKs 
phosphorylate Serine and Threonine residues of various target substrates, contributing to the 
regulation of cell proliferation and apoptosis, orchestrating both tumor suppressing and 
activating responses (Davis, 2000). While JNK1 and JNK2 are expressed ubiquitously, JNK3 
is rather abundant in the brain. The JNKs are key players in the developing and adult brain, 
where different isoforms and splice variants of JNKs are differentially expressed (Brecht et 
al., 2005; Coffey, 2014). 
Several studies indicated interactions between JNK proteins and the Hedgehog-GLI pathway 
(Amable et al., 2014; Laner-Plamberger et al., 2009; Liu et al., 2015). For example, basic 
fibroblast growth factor was shown to block SHH signaling in granule cell precursors and 
medulloblastoma tumor cells in vitro and in vivo in mice by predominantly JNK-mediated 
mechanisms (Fogarty et al., 2007). Additionally, the increased JNK1 phosphorylation 
induced by H2O2 treatment was correlated with decreased expression of Hedgehog signaling 
genes and GLI1 activity in fibroblast cells (Shiohama et al., 2014). In another study, 
Whisenant et al. predicted a new MAPK docking-site on GLI3 protein (residues 281-300), 
and by mass spectrometry have further confirmed that phosphorylation of Serine 343 on 
GLI3 is JNK1-3-mediated and docking-site-dependent. Computational analysis also 
pinpointed highly similar docking-sites on GLI1 and GLI2. In particular, they found a 
homologue docking-site on GLI1 (residues 72-91) mediating the binding of JNK1-3 to GLI1, 
Figure 2. A schematic diagram representing the crosstalk of 
Hedgehog and other signaling pathways.
WNT signaling or growth factor FGF, VEGF pathways can
crosstalk with Hedgehog signaling during tissue development
or orchestrate tumorigenesis. SHH levels can be regulated by
K-RAS or ER-alpha. Depending on the cellular context and
upstream activating events, GLI levels can be regulated by
RAS family of GTPases, e.g. PI3K/AKT, RAF/MEK,
JNK/MAPK which can act as powerfull oncogenes in various
human tumors. TGF-beta ligands can induce GLI expression
independent of SMO. The p53 pathway can antagonise
Hedgehog-GLI.
Abbreviations. WNT: wingless, FGF: fibroblast growth factor,
VEGF: vascular endotelial growth factor, PI3K: phophoinositide 3-
kinase, AKT: protein kinase B, MEK: mitogen-activated protein
kinase kinase, JNK: JUN amino-terminal kinase, TGF:
transforming growth factor.
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which promotes phosphorylation of target sites within GLI1 (residues 68-232) and 
specifically, Serine 130 (Whisenant et al., 2010). 
1.1.4.2 p53 tumor suppressor mediated regulation of Hedgehog-GLI 
The paramount role of p53 as a tumor suppressor is well known, and the majority of cancers 
carry inactivating mutations of p53 or de-regulation of the p53 pathway (Soussi and Wiman, 
2015; Zawacka-Pankau and Selivanova, 2015). 
Several studies suggested a negative regulatory loop between Hedgehog and p53 signaling, 
although yet little is known about the mechanisms underlying this interplay (Mazza et al., 
2013; Stecca and Ruiz i Altaba, 2009). p53 has been suggested to negatively regulate the 
activity, nuclear localization and levels of GLI1 in neural stem cells and brain tumor cells, 
while GLI1 knockdown increased protein levels of p53 and active phospho-serine15 p53 in 
primary glioblastoma cells (Stecca and Ruiz i Altaba, 2009). This negative regulatory loop 
can be also maintained by competitive p53 and GLI1 binding to the coactivator TATA-box 
binding protein associated factor 9 (TAF9) (Yoon et al., 2015). Another possible mechanism 
is the Hedgehog signaling-mediated phosphorylation and activation of MDM2, which 
promotes p53 ubiquitination and inhibits p53-mediated apoptosis (Abe et al., 2008). 
Additionally, it was suggested that p53 can activate a novel PTCH1 homolog (PTCH53), 
resulting in suppression of Hedgehog signaling (Chung et al., 2014). 
Given the importance of p53 as a crucial tumor suppressor and the evidence of a negative 
regulatory loop between Hedgehog and p53 signaling, we were inspired to restore the p53 
function in Hedgehog-dependent tumor cells (PAPER I). 
1.2 Hedgehog signaling in human cancers 
Inappropriate activation of Hedgehog signaling has been linked to hyperproliferation and 
cancer development, including medulloblastoma, rhabdomyosarcoma, basal cell carcinoma, 
cancers of the lung, stomach, pancreas, colon and prostate (Aberger and Ruiz, 2014; Altaba et 
al., 2002; Amakye et al., 2013; Ng and Curran, 2011; Pietrobono et al., 2019; Skoda et al., 
2018; Teglund and Toftgård, 2010), accounting for about 25% of human cancer deaths (Lum 
and Beachy, 2004). In this thesis we will mainly focus on medulloblastoma, 
rhabdomyosarcoma and breast cancer. 
1.2.1 Hedgehog pathway activity and oncogenic drivers 
Mechanisms linking constitutive activation of the Hedgehog pathway to tumorigenesis 
include ligand-independent mutations of key players of the pathway, ligand-dependent 
autocrine and paracrine activation, and finally cancer stem cell-driven activation of Hedgehog 
signaling. 
The first evidence of oncogenesis and mutation-driven mechanism in the Hedgehog pathway 
was observed in the nevoid basal cell carcinoma syndrome, also known as Gorlin syndrome, 
with inherited loss of function mutations in one allele of the PTCH1 gene. Somatic 
  7 
inactivation of the other PTCH1 allele was demonstrated to result in development of basal 
cell carcinoma (Hahn et al., 1996b; Johnson et al., 1996). Interestingly, these loss of function 
heterozygous mutations of PTCH1 were also shown to lead to the development of primitive 
neuroectodermal tumors of cerebellum, medulloblastomas (Raffel et al., 1997; Yang et al., 
2008) and rhabdomyosarcomas (Tostar et al., 2006). Loss of function mutations of SUFU, 
another negative regulator of the Hedgehog pathway, have been observed in basal cell 
carcinoma, medulloblastoma, rhabdomyosarcoma (sporadic mutations) and Gorlin syndrome-
associated childhood medulloblastoma (germline mutations) (Lee et al., 2007; Smith et al., 
2014; Taylor et al., 2002; Tostar et al., 2006). 
Another significant driver of Hedgehog-dependent tumorigenesis are gain of function 
mutations and/or amplifications of positive regulators of Hedgehog signaling. Such are 
activating mutations of SMO in basal cell carcinoma and medulloblastoma (Reifenberger et 
al., 1998; Xie et al., 1998), GLI1 amplifications in gliomas, medulloblastomas and 
rhabdomyosarcomas, and GLI2 amplifications in medulloblastoma (Amakye et al., 2013; 
Kool et al., 2014; Nilsson et al., 2000; Roberts et al., 1989). 
The complete relevance of ligand-dependent activation of Hedgehog signaling as a major 
driver of cancer is less clear, since it is more complex and involves multiple intrinsic and 
extrinsic factors, including the tumor itself, tumor microenvironment and adjacent tissues, as 
well as various possible multiplex crosstalks between these compartments. Ligand-dependent 
autocrine activation of the Hedgehog pathway through elevated expression of Hedgehog 
ligands was demonstrated in cancers of lung, breast, stomach and prostate (Amakye et al., 
2013). 
Ligand-dependent paracrine activation involves increased secretion of Hedgehog ligands by 
the tumor cells, which further expand and trigger Hedgehog pathway activation in the tumor 
microenvironment, composed of surrounding normal and tumor supporting stromal cells. In 
turn, activated stroma stimulates growth of the tumor by various signaling mediators, 
including Insulin-like growth factor, WNT, Interleukin-6 and Vascular endothelial growth 
factor. This type of signaling may play a role in solid tumor types, which rarely harbor 
mutations in Hedgehog genes, e.g. ovarian, pancreatic and colorectal cancers (Yauch et al., 
2008). 
Finally, Hedgehog signaling is believed to contribute to the maintenance and determination of 
cancer stem cells in breast, colon, pancreatic cancer and glioblastoma (Bar et al., 2007; 
Merchant and Matsui, 2010). Considering the role of Hedgehog signaling in embryogenesis 
and cell fate determination, and the fact that later in normal adult tissues Hedgehog signaling 
is mainly active in precursor cells, it has been argued that the Hedgehog-associated tumors 
can be derived from precursor and stem cells (Ruiz i Altaba et al., 2002). 
1.2.2 Hedgehog signaling in medulloblastoma 
Medulloblastoma is a highly aggressive class of brain tumors, with highest occurrence among 
childhood brain tumors. Medulloblastoma originates from cerebellar progenitor cells and 
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exhibits considerable genomic heterogeneity, which defines distinct clinical subsets of this 
disease. Currently four large molecular subgroups of medulloblastomas are recognized: WNT 
(10%), SHH (30%), group 3 (25%) and group 4 (35%) (Juraschka and Taylor, 2019; Rusert 
et al., 2014). Conventional therapies of medulloblastomas are implemented through invasive 
methods such as surgery, radiotherapy and high-dose cytotoxic chemotherapy. Targeted 
therapy based on molecular classification of the tumor could improve the disease risk and 
minimize general toxicity of the treatment. 
SHH plays critical roles in controlling the development of cerebellum, influencing cell 
proliferation, differentiation and migration. SHH medulloblastomas are known to arise from 
cerebellar granule neuron progenitors derived from the external granule cell layer, cochlear 
nuclei of the brainstem, and also neural stem cells residing in the subventricular zone (Altaba 
et al., 2002; Northcott et al., 2012b). Amplifications and mutations of Hedgehog pathway 
components (PTCH1, GLI2, GLI1, SMO) are common drivers of SHH medulloblastomas. 
Loss of function mutations of PTCH1 are found in about 20% of sporadic medulloblastomas 
(Raffel et al., 1997). Mutations in SMO and SUFU are less frequent (Taylor et al., 2002; 
Zurawel et al., 2000), although activation of SMO results in early cerebellar 
hyperproliferation and high rate of medulloblastoma formation (Hallahan et al., 2004; Hatton 
et al., 2008). 
Amplifications of GLI2 and another oncogene MYCN are also considered as common drivers 
of SHH medulloblastomas (Dahmane et al., 2001; Kool et al., 2014; Northcott et al., 2012b). 
GLI1 has been suggested to induce expression of the SNAIL1 transcription factor, which in 
turn regulates MYCN, thus mediating the transition of oncogenic cerebellar granule neuron 
progenitor cells into medulloblastoma (Wanshura et al., 2011). In mouse model studies, 
Kimura et al. have demonstrated that medulloblastoma formation was significantly reduced in 
Ptch1+/-, Gli1-/- mice, i.e. in the absence of functional GLI1. Interestingly, Ptch1+/-, Gli1+/- 
and Ptch1+/-, Gli1-/- mice had higher expression of Gli2 (Kimura et al., 2005). These 
observations indicate that first, GLI1 plays a crucial role in formation of medulloblastoma 
tumors, and second, increased GLI2 expression may compensate for the reduced level of 
GLI1, further regulating target genes responsible for tumor formation in these mice. 
In addition, SHH medulloblastomas can also harbor recurrent mutations in the p53 gene. 
Medulloblastoma formation is dramatically accelerated in double knockout mice with 
heterozygous defective PTCH (Ptch1+/-) and homozygous defective p53 (p53-/-), where 
almost 95% of these mice develop medulloblastoma by the 12 weeks of age (Wetmore et al., 
2001). Possible mechanism for this increased tumor frequency could be the interruption of 
the GLI1-p53 negative regulatory loop in neural precursor cells (Stecca and Ruiz i Altaba, 
2009). In fact, p53 gene mutations are particularly enriched in SHH medulloblastomas 
(Zhukova et al., 2013), and patients with p53 mutated SHH medulloblastomas are at very 
high risk of reduced survival and almost always fail therapy (Ramaswamy et al., 2016). Thus, 
PTCH1 loss of function provides a stronger selective advantage in medulloblastoma 
development, and loss of p53 activity results in substantial enhancement of tumors. 
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Overall, among Hedgehog-linked tumors, medulloblastoma is one of the well-understood 
from the Hedgehog pathway perspective. Still, better understanding of the biology of 
medulloblastoma and approaches focusing on selective targeting of key drivers of the disease, 
such as Hedgehog-components and p53, could provide promising therapeutic outcomes. 
1.2.3 Hedgehog signaling in rhabdomyosarcoma 
Rhabdomyosarcoma originates from the skeletal muscle precursor cells, is highly malignant 
and is the most common soft tissue sarcoma in childhood (Walsh and Hurt, 2008). Two major 
histological subtypes are known: embryonal and alveolar rhabdomyosarcomas. Sporadically 
occurring rhabdomyosarcomas are characterized with hyperactive Hedgehog signaling, which 
is highlighted by elevated GLI1 and PTCH1 expression (Roberts et al., 1989; Zibat et al., 
2010), and loss of heterozygosity of PTCH1 and/or SUFU, and HHIP (Tostar et al., 2006; 
Uhmann et al., 2005). Other studies also support the involvement of Hedgehog signaling in 
embryonal rhabdomyosarcoma tumors with frequent loss of chromosomal regions 
corresponding to PTCH1 9q22 and gain of the GLI1 locus at 12q13-15 (Bridge et al., 2000). 
Like medulloblastomas, rhabdomyosarcoma development and frequency can also depend on 
the genetic background. In experimental mouse models homozygous removal of the p53 gene 
on the background of activated Hedgehog signaling can increase the incidence of 
rhabdomyosarcomas (Teglund and Toftgård, 2010). 
1.2.4 Hedgehog signaling in breast cancer 
Breast cancer is the leading cause of cancer-related deaths and the most common cancer in 
women (Harbeck et al., 2019). It is a heterogeneous disease and molecular profiling of breast 
cancer tumors is generally defined by the expression of estrogen and progesterone hormone 
receptors, human epidermal growth factor receptor 2 (HER2) tyrosine kinase and the nuclear 
marker of cell proliferation Ki-67. Due to the high heterogeneity of breast cancer subtypes, 
the treatment response to therapeutic agents varies, suggesting deregulation of other 
oncogenes (Riobo-Del Galdo et al., 2019). 
Possible crosstalk between Hedgehog signaling activation and the development of breast 
cancer has been widely studied (Flemban and Qualtrough, 2015; Hui et al., 2013). Transgenic 
mice with conditional overexpression of GLI1 were shown to develop mammary tumors 
(Fiaschi et al., 2009; Hui et al., 2013). Several studies have indicated activation of Hedgehog 
signaling and increased GLI1 expression in subsets of breast cancers and cell lines (Bhateja et 
al., 2019; Mukherjee et al., 2006; Riobo-Del Galdo et al., 2019). It was suggested that 
increased GLI expression and activated Hedgehog signaling may drive estrogen-dependent 
stem cell development and epithelial-mesenchymal transition in estrogen receptor-alpha (ER-
alpha) positive breast cancer cells (Sun et al., 2014). Moreover, Hedgehog signaling activity 
and GLI1 nuclear translocation was shown to be increased by estrogen stimulation, 
enhancing invasiveness of breast cancer cells (Souzaki et al., 2011; Visbal et al., 2011). 
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Additionally, non-canonical activation of Hedgehog signaling through PI3K/AKT pathway 
has been suggested to mediate tamoxifen resistance in breast cancer cells. In this study, 
tamoxifen resistant cells had elevated levels of GLI1, SMO and increased GLI1 
transcriptional activity, compared to tamoxifen sensitive cells. Moreover, Hedgehog signaling 
inhibition suppressed the growth of tamoxifen resistant breast cancer cells in vitro and in vivo 
mouse xenografts (Ramaswamy et al., 2012). In Paper II, we have further investigated the 
mechanisms underlying the role of Hedgehog-GLI signaling in breast cancer and the possible 
role of GLI1 as a therapeutic target. 
1.3 Therapeutic approaches for Hedgehog-activated tumors 
Hedgehog signaling can be targeted at many levels. The strategies to suppress aberrantly 
activated Hedgehog signaling in different cancers have focused on inhibition of key players 
of the “canonical” and “non-canonical” Hedgehog pathway. Currently, these include 
extracellular blockade of Hedgehog ligands, inhibition of SMO or repression of GLI action in 
the cells. 
1.3.1 SMO inhibitors 
Early inhibitors of the Hedgehog pathway were mainly focused on targeting SMO. 
Cyclopamine is the most extensively studied SMO inhibitor (Chen et al., 2002). It was 
initially isolated from corn lily and demonstrated high efficiency in preclinical studies, but 
failed clinical development due to poor pharmacokinetic features and general toxicity 
(Amakye et al., 2013). Since then, efforts to improve the chemical stability and efficacy of 
cyclopamine have led to the identification of its more potent derivatives and analogs, such as 
saridegib (IPI-926), vismodegib (GDC-0449) and sonidegib (LDE-225). In fact, vismodegib 
was the first Hedgehog pathway targeting drug approved by the U.S. Food and Drug 
Administration (FDA) for locally advanced and metastatic basal cell carcinoma (Sekulic et 
al., 2012). Later in 2015, sonidegib was also approved for locally advanced basal cell 
carcinoma (Migden et al., 2015). Together with other derivatives (IPI-926, BMS-833923, PF-
04449913, LY2940680) (Jimeno et al., 2013; LoRusso et al., 2011; Rodon et al., 2014), these 
drugs are currently undergoing clinical trials for other cancers, including medulloblastoma, 
colorectal and advanced pancreatic cancer (Amakye et al., 2013; Cortes et al., 2019; Pak and 
Segal, 2016). 
However, cases of cross-resistance or acquired resistance against SMO inhibitors have 
already been reported in basal cell carcinoma and medulloblastoma (Chang and Oro, 2012; 
Jimeno et al., 2013; Rudin et al., 2009). Acquired resistance to SMO inhibitors has mainly 
been linked to mutations in SMO (Atwood et al., 2015; Rudin et al., 2009; Sharpe et al., 
2015). Moreover, resistant tumors often harbor mutations in other Hedgehog pathway genes, 
such as mutations in SUFU, amplification or activation in the downstream regulators GLI2 
and GLI1 (Dijkgraaf et al., 2011; Metcalfe and de Sauvage, 2011). Additionally, tumor 
drivers beyond the Hedgehog pathway genes may also explain some of the clinically 
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heterogenic responses to SMO inhibition, demonstrated in basal cell carcinoma and 
medulloblastoma (Bonilla et al., 2016; Kool et al., 2014). 
Preclinical studies have also revealed complications associated with toxicities of SMO 
inhibitors, including taste disturbance, alopecia, muscle spasms, anorexia, fatigue, bone and 
dental toxicities (Amakye et al., 2013; Kimura et al., 2008). Moreover, administration of 
higher doses of vismodegib does not enhance its effects, but rather escalates systemic 
toxicity. Higher dose application of sonidegib, saridegib and BBS-833923 instigate specific 
adverse effects on the levels of liver enzymes, serum lipase and creatine kinase (reviewed in 
(Amakye et al., 2013)). 
Due to complications with acquired resistance and toxicity, inhibition of SMO alone may not 
provide sufficient therapeutic benefits. Instead, combinations with other agents may lead to 
more beneficial outcomes. Notably, since the GLI proteins are the terminal effectors of 
Hedgehog signaling, their effective inhibition can be particularly attractive. The increased 
awareness of SMO-independent GLI activation further highlights the importance of targeting 
GLI. 
1.3.2 GLI inhibitors 
The most promising targets downstream of SMO are the GLI transcription factors. Compared 
to the various SMO inhibitors, currently there are fewer drugs in the market targeting the GLI 
factors. Examples of early GLI inhibitors are itraconazole and arsenic trioxide, which have 
been approved by FDA, and both entered clinical trials for basal cell carcinoma (Kim et al., 
2013). More recently identified small molecule Glabrescione B was shown to directly bind to 
GLI1 and impair GLI1 transcriptional activity by interfering with GLI1-DNA interaction and 
resulting in inhibition of the Hedgehog signaling in medulloblastoma, basal cell carcinoma 
and pancreatic tumor cells in vitro and in vivo mouse xenografts (Infante et al., 2015; 
Ingallina et al., 2017). In a cell-based screen for small molecule inhibitors of GLI, two other 
selective drugs (GANT61 and GANT58) have been discovered to suppress GLI1 and GLI2-
mediated gene transactivation (Lauth et al., 2007). Further investigation of the relatively more 
potent agent GANT61 has proven its high efficacy in suppressing Hedgehog signaling-
dependent growth in different cancer cell types and respective animal models, including 
rhabdomyosarcoma (Tostar et al., 2010), neuroblastoma (Wickström et al., 2013), prostate 
(Lauth et al., 2007), pancreatic (Fu et al., 2013), hepatocellular (Wang et al., 2013), breast 
(Benvenuto et al., 2016; Neelakantan et al., 2017) and small cell lung (Huang et al., 2014) 
cancers. 
Initially GANT61 was proposed to induce possible modification of GLI1 protein, without 
altering DNA binding of GLI1 (Lauth and Toftgard, 2007). In line with this, later it has been 
suggested that GANT61 binds to the GLI1 protein in a groove between Zinc-finger 2 and 3, 
at sites E119 (1 hydrogen bond) and E167 (2 hydrogen bonds), distinct from the GLI1 DNA 
binding region. Interestingly, these binding sites are conserved between GLI1 and GLI2, 
which can explain the inhibitory effect of GANT61 also on GLI2 (Agyeman et al., 2014; 
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Calcaterra et al., 2018). Lauth et al. also proposed a possible high instability of GANT61 
molecule in acidic and aqueous solutions, which rapidly disassociates into a diamine 
(GANT61-D) and a benzaldehyde (GANT61-A) substructures. Notably, only the diamine but 
not the aldehyde derivative was capable of inhibiting Hedgehog signaling with a comparable 
efficacy compared with parental GANT61 molecule (Lauth et al., 2010). In addition, a recent 
study confirmed that in physiological conditions GANT61 hydrolyses into GANT61-A and 
GANT61-D, but with GANT61-D exhibiting slightly higher bioactivity in mediating GLI1 
expression levels and expressing highest affinity to GLI1 Zinc-finger 1 and 2 (Calcaterra et 
al., 2018). 
1.3.3 RITA as an inhibitor of Hedgehog-GLI signaling 
Misregulation of the p53 pathway exhibited by inactivating recurrent mutations in the p53 
gene or a p53-null background can dramatically enhance tumorigenesis. In Hedgehog-
activated cancers, such as medulloblastoma and rhabdomyosarcoma, in addition to targeting 
Hedgehog signaling, strategies aiming at restoring p53 function may provide certain 
advantages. Restoration of mutant p53 activity is especially attractive, since mutant p53 
proteins are usually selectively highly expressed and accumulated in tumors, thus targeting 
mutant p53 principally should not affect normal tissues (Selivanova and Wiman, 2007). A 
number of small molecules reactivating mutant p53 have been identified, including PRIMA-1 
(Bykov et al., 2002), RITA (Issaeva et al., 2004), APR-246 (Bykov and Wiman, 2014). 
Small molecule NSC652287, later named RITA (reactivation of p53 and induction of tumor 
cell apoptosis) was identified as a potential tumor suppressor (Nieves-Neira et al., 1999; 
Rivera et al., 1999). It was discovered in a cell-based screening assay, which differed only in 
the p53 status of the cells analyzed, thus this inhibitory drug was claimed to exert its effects 
in a p53-dependent manner, through downregulation of a number of oncogenes and activation 
of survival genes, resulting in cancer cell apoptosis and growth suppression in a dose-
dependent manner (Grinkevich et al., 2009; Issaeva et al., 2004; Nieves-Neira et al., 1999; 
Nikulenkov et al., 2012). It was suggested that RITA binds to the amino-terminus of p53, 
blocking its interaction with MDM2, a negative regulator of p53 (Issaeva et al., 2004). Later 
it was demonstrated that RITA can induce DNA damage and interact with Thioredoxin 
reductase 1 (TrxR1), leading to ROS induction (Hedström et al., 2009). ROS-dependent JNK 
activation was suggested as one possible mechanism of RITA action (Hedström et al., 2009; 
Shi et al., 2014; Weilbacher et al., 2014). Notably, RITA was found to be an efficient 
activator of both wild type and mutant p53 in a panel of neuroblastoma cell lines (Burmakin 
et al., 2013). Additionally, it is possible that nonmalignant cells (fibroblast, peripheral blood 
mononuclear cells) are substantially less sensitive to RITA compared to tumor cells, making 
RITA a valuable tumor-selective drug (Saha et al., 2010; Weilbacher et al., 2014). 
Intriguingly, further studies suggested p53-independent effects of RITA, questioning its 
selective binding to p53 (Krajewski et al., 2005) and suggesting that p53 might be 
dispensable for RITA activity, as its effects are largely mediated through induction of DNA 
damage (Wanzel et al., 2016) or inhibition of mRNA translation by inducing phosphorylation 
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of the alpha subunit of the eukaryotic translation initiation factor 2 (elF2-alpha) (Ristau et al., 
2019). Indeed, it was reported that RITA could inhibit the growth and induce senescence of 
head and neck cancer cells, irrespective of the p53 status (Chuang et al., 2014). Weilbacher et 
al. demonstrated that whereas p53 has a central role for RITA-mediated effects in wild type 
p53 cells, neither p53, nor the other two homologs of p53 (p63 or p73) are essential for the 
RITA response in mutant or p53-null cells. They also suggested, that RITA-induced 
apoptosis is predominantly mediated by JNK/SAPK and p38 MAPK pathways (Weilbacher 
et al., 2014). 
Still very little is known about RITA transport into the cells and the question why different 
cells respond variably to RITA is still open. This might be due to differential uptake, 
accumulation and metabolism of the drug, but the exact mechanisms that impinge on RITA 
activity are a matter of further investigation.  
In PAPER I, we have reported a p53-independent action of RITA and showed that RITA can 
effectively downregulate Hedgehog signaling in vitro and suppress rhabdomyosarcoma-cell 
xenograft tumor growth in vivo. In addition, we have addressed the combinatorial effects of 
RITA and GANT61 in medulloblastoma and rhabdomyosarcoma cells in vitro and in vivo. 
1.4 Circular RNAs 
Circular RNAs (circRNAs) in eukaryotes were identified few decades ago (Cocquerelle et al., 
1993; Nigro et al., 1991; Zaphiropoulos, 1996) and until recently have been largely neglected 
as rare and non-functional by-products of the splicing machinery. However, with the advent 
of next generation sequencing they have been re-discovered as a new class of ubiquitously 
expressed and biologically functional non-coding RNA molecules. 
1.4.1 Biogenesis 
circRNAs are unique by their secondary structure and are generated from canonical splice 
sites through alternative splicing, when the 3’ end of a downstream exon “back-splices” to the 
5’ end of an upstream exon producing a covalently closed loop (Figure 3). The back-splicing 
is catalyzed by the canonical spliceosome machinery and can be facilitated by several factors. 
The presence of intronic inverted repeats is one of the prevalent features of circRNAs. Introns 
flanking the circularized exons appear to be enriched with Alu repetitive elements, which can 
significantly contribute to circRNA biogenesis (Jeck et al., 2013; Liang and Wilusz, 2014). 
Additionally, tissue specific exon circularization can be facilitated by RNA-binding proteins, 
such as the splicing factors muscleblind in Drosophila and Quaking (Ashwal-Fluss et al., 
2014; Conn et al., 2015). An exon skipping event during linear splicing, via the formation of 
a lariat structure encompassing the skipped exons, can also contribute to circRNA biogenesis 
(Barrett et al., 2015; Zaphiropoulos, 1997). On the other hand, the RNA editing enzyme 
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ADAR1 that binds RNA in double stranded regions can act as an inhibitor of circRNA 
production by destabilizing the pairing between complementary motifs present in the flanking 
introns of circularizing exons (Rybak-Wolf et al., 2015). 
 
1.4.2 Detection 
Apart from the lack of a poly(A) tail, another key characteristic of circular transcripts is the 
presence of a back-spliced junction, which makes them distinguishable from their linear 
counterparts. Because of these unique features, circRNAs are lost in standard RNA-seq 
profiling or even in PCR assays that are usually enriched for poly(A) RNAs and detect 
forward-spliced junctions. Thus, to identify circRNAs some additional modifications of 
standard protocols need to be implemented. These include depletion of ribosomal RNA by 
methods such as riboZero techniques, and treatment with RNAse R, a ribonuclease that 
degrades linear but not circRNAs. Additionally, reverse transcription (RT) should be done 
using random hexamers instead of oligo(dT) primers (Szabo and Salzman, 2016). 
Once a circRNA enriched preparation is subjected to RNA-seq, specific bioinformatic 
algorithms based on detection of back-spliced junction have to be used. Such algorithms are 
constantly being developed and updated, for example CIRI 
(https://sourceforge.net/projects/ciri-full/) and CIRCexplorer 
(https://circexplorer2.readthedocs.io/en/latest/) (Hansen et al., 2016). A few important factors 
to consider are the mapper (i.e. TopHat, STAR, Bowtie) and the associated stringency criteria 
employed by different algorithms, as their false-positive rates can vary considerably  
(Kristensen et al., 2019). 
The information about genomic positions of back-spliced junctions can be used for 
experimental validations of computationally predicated circRNAs. RT-PCR based assays are 


















Figure 3. Circular RNA biogenesis.
Genes produce not only linear mRNAs, but also
circular RNAs. Circularization occurs via back-
splicing of exons. In this illustration, exon 3 back-
splices to exon 2 to produce a circular RNA. This
is facilitated by inverted repeats in the introns
flanking the back-spliced exons.
In the nucleus, circular RNAs can regulate their
parental gene activity. In the cytoplasm, circular
RNAs can act as miRNA sponges and limit their
interaction with cognate mRNAs. They can also
function as sponges or decoys for RNA-binding
proteins (RBP) and thus regulate their activity.
Circular RNAs can be translated giving rise to
unique peptides. Finally, circular RNAs can serve
as diagnostic and prognostic biomarkers.
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most frequently used, where divergent primers are designed to amplify the back-spliced 
junction on random hexamers primed cDNA. Additionally, Sanger sequencing validation of 
the resulting PCR product can confirm the presence of a back-spliced junction. Quantitative 
qPCR assays can be used to determine the abundance of a circRNA transcript relative to a 
housekeeping gene, while droplet digital PCR can determine the absolute concentrations 
using the ratio of positive to negative droplets. Northern blotting can have certain advantages, 
as it does not include RT or amplification steps, although here the procedures are more time-
consuming and large quantities of starting RNA material are required. It is also possible to 
visualize circRNAs in cells or tissue samples by RNA in situ hybridization with 
oligonucleotide probes (Kocks et al., 2018; Kristensen et al., 2019; Li et al., 2018). In all 
these settings, great care should be taken to differentiate the circular transcript from the linear 
mRNAs originating from the same parental gene. 
1.4.3 Functions 
In contrast to early views, there is now a compelling evidence that circRNAs are stably and 
abundantly expressed in eukaryotic cells, approximately 2-4% of the total mRNA (Szabo and 
Salzman, 2016), and in some cases even more abundant than the mRNAs originating from 
the same gene (Jeck et al., 2013; Salzman et al., 2012). circRNA transcripts can be 
ubiquitously expressed in a cell and tissue-specific manner and regulate various biological 
processes (Ji et al., 2019; Maass et al., 2017; Memczak et al., 2013; Salzman et al., 2012; Vo 
et al., 2019), including brain function (Piwecka et al., 2017; Rybak-Wolf et al., 2015). 
In general, circRNAs are expected to have different functions from their linear counterparts. 
Even though compared to mRNAs, circRNAs are generally expressed at lower levels, it is 
likely that a co-transcriptional competition may exist between back-splicing and canonical 
forward-splicing, especially for loci that extensively produce circRNAs (Kristensen et al., 
2019). 
circRNAs can act as molecular traps for microRNAs (miRNAs) and inhibit the bioavailability 
of miRNAs to interact with their target mRNAs. miRNAs are known to regulate gene 
expression by suppressing translation and enhancing exonucleolytic degradation of mRNAs. 
The increased stability of circRNAs with no free 5’ or 3’ ends makes them inherently 
resistant to miRNA-mediated exonucleolytic degradation and fits well with a role in 
sequestering miRNAs (Ebbesen et al., 2017; Yu et al., 2018). 
circRNAs can interact with RNA-binding proteins and possibly function as scaffolds for 
protein interactions (Ebbesen et al., 2017; Feng et al., 2019; Xia et al., 2019). Such an 
example is circFOXO3 derived from the tumor suppressor gene FOXO3, which possesses 
binding sites for MDM2, the negative regulator of p53, and inhibits MDM2-dependent 
FOXO3 degradation while facilitating MDM2-induced p53 degradation (Du et al., 2017). 
While most of the exonic circRNAs are localized in the cytoplasm, some exon-intron 
circRNA transcripts generated from intronic lariats are restricted to the nucleus where they 
can interfere with the transcription of their parental genes. For example, some such circRNA 
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transcripts were shown to regulate RNA Polymerase II-mediated transcription (Bose and Ain, 
2018; Ebbesen et al., 2017).  
Although circRNAs are generally considered as a non-coding class of RNA molecules, their 
predominant accumulation in the cytoplasm may support a cap-independent translation of 
circRNAs with an AUG start codon and an internal ribosomal entry sites (Zeng et al., 2017). 
circRNAs can be present not only inside the cell but also circulate in the extracellular plasma, 
blood and saliva (Memczak et al., 2015) or be transported by exosomes (Li et al., 2015). Such 
tumor-derived circRNAs can be promising diagnostic biomarkers. 
1.4.4 Circular RNAs in cancer 
Owing to their high stability, circRNAs accumulate in the cytoplasm, particularly in cells 
with low proliferation rates. For example, circRNAs are rather abundant in the brain and in 
developing neurons (Maass et al., 2017; Piwecka et al., 2017; Rybak-Wolf et al., 2015), while 
they are predominantly downregulated in cancer (Bachmayr-Heyda et al., 2015; Kristensen et 
al., 2018; Lv et al., 2018). It is yet not fully clear whether circRNAs are preferentially 
expressed in cells with low proliferation rates or their abundancy is diluted out by high cell-
proliferation rates before reaching steady state levels (Holdt, 2018; Sharova et al., 2009). 
A growing number of studies report hundreds of circRNAs deregulated in distinct human 
cancers, including colorectal (Hsiao et al., 2017), hepatic (Yu et al., 2018), prostate (Chen et 
al., 2019), bladder cancer (Li et al., 2017) and tumors of central nervous system (Kristensen 
et al., 2018; Lv et al., 2018; Vo et al., 2019). In this thesis we aim to study the role of 
deregulated circRNAs in the context of Hedgehog-activated medulloblastoma tumors and 
how they may impact the development of this cerebellar cancer (PAPER IV, manuscript). 
 
  17 
2 Aims of the thesis 
General aim: 
Hedgehog signaling is one of the major pathways involved in both normal and neoplastic 
development. This thesis aimed at the elucidation of mechanisms that regulate Hedgehog-
GLI signaling activity contributing towards a better understanding of Hedgehog-mediated 
cancer development. 
Specific aims: 
I. Investigate the role of small molecular drug RITA in downregulation of Hedgehog-GLI 
signaling in medulloblastoma and rhabdomyosarcoma. 
II. Investigate the role of GLI1 as a therapeutic target for estrogen receptor positive breast 
cancer. 
III. Global analysis of GLI1 target genes and their role in biological processes mediated by 
GLI1. 
IV. Address the role of a new class of RNA molecules, circular RNAs, in the context of 
activated Hedgehog signaling and the Hedgehog subtype of medulloblastoma. 
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3 Results and conclusions 
3.1 PAPER I 
RITA downregulates Hedgehog-GLI in medulloblastoma and rhabdomyosarcoma via 
JNK-dependent but p53-independent mechanism 
Medulloblastoma and rhabdomyosarcoma are heterogeneous and aggressive classes of 
childhood tumors with subtypes characterized by abnormally activated Hedgehog signaling. 
Additionally, frequent defects in p53 signaling are known to dramatically enhance these 
tumors (Juraschka and Taylor, 2019; Northcott et al., 2012a; Roberts et al., 1989; Teglund 
and Toftgård, 2010; Tostar et al., 2010). 
In this study, we mainly focused on two human tumor cell lines of distinct origin and p53 
background: Rh36 rhabdomyosarcoma cells with wild type p53 and Daoy medulloblastoma 
cells carrying a homozygous Cysteine to Phenylalanine mutation in codon 242 of the p53 
gene (Metzger et al., 1991; Saylors et al., 1991). 
Small molecule RITA (Issaeva et al., 2004) effectively downregulated Hedgehog signaling 
irrespective of the p53 status (wild type or mutant) in the cells or p53 depletion via siRNAs. 
This was demonstrated in three different cellular contexts, Daoy, Rh36 and MCF7 breast 
cancer cells (wild type p53), where RITA was capable to downregulate expression of typical 
Hedgehog target genes (GLI1, GLI2, PTCH1, PTCH2). Moreover, RITA was able to reduce 
Hedgehog signaling activity even in the context of pathway activation by Smoothened 
agonist SAG or GLI1 plasmid overexpression in Daoy cells. Interestingly, in mouse 
embryonic fibroblast cells where the negative regulators of Hedgehog signaling, the PTCH1 
(Ptch-/-) and SUFU (Sufu-/-) are eliminated, RITA was rather inefficient at downregulating 
Hedgehog target genes, and only at very high concentrations induced a detectable reduction 
in the Ptch-/- cells. Noteworthy that in line with this, RITA did not induce p53, nor was it able 
to effectively suppress the growth of several mouse cell lines in a previously published study 
(Issaeva et al., 2004). 
These effects of RITA are apparently elicited downstream of SMO, as siRNA depletion of 
SMO did not confer major changes in the response of the Hedgehog target genes. Notably, 
qPCR analysis of p53 target genes remaining mostly unchanged, and Western blot analysis of 
p53 protein levels remaining unchanged upon RITA treatment, further supported p53-
independent effects of RITA, in line with other studies (Krajewski et al., 2005; Wanzel et al., 
2016; Weilbacher et al., 2014). Nor RITA effects were mediated by the two other p53 
homologs, p63 and p73, as their siRNA depletion did not affect downregulation of Hedgehog 
target gene expression by RITA. 
Suppression of Hedgehog signaling by RITA was mediated by ROS-independent activation 
of JNK kinase, as inhibition of JNK but not of ROS accumulation fully reverted RITA's 
impact on Hedgehog target genes. Here, first, ROS accumulation was prevented by different 
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antioxidants (resveratrol and NAC) and second, JNK activity was inhibited by the small 
molecule SP600125 in Daoy and Rh36 cells. Western blot analysis confirmed that the protein 
levels of the JNK isoforms were elevated by activating phosphorylation upon RITA treatment 
in Daoy cells. 
Compared to the DNA damaging agents Doxorubicin and Oxaliplatin, RITA had distinct 
cytotoxic readouts in cell viably assays and differential impact on Hedgehog signaling. Worth 
noting is that two other p53 activating drugs, nutlin-3a and APR-246 (PRIMA-1Met) (Bykov 
and Wiman, 2014), were rather ineffective in downregulating Hedgehog target genes, again, 
highlighting the distinct action of RITA on Hedgehog signaling. 
RITA, in combination with GANT61, a small molecule inhibitor of Hedgehog signaling, 
elicited more pronounced reduction of tumor cell proliferation than individual drug 
treatments assessed by in vitro cell proliferation and apoptosis assays. This was not fully 
reflected in the in vivo Rh36 cell subcutaneous xenograft studies in nude mice, as the 
combinatorial and individual administrations of RITA and GANT61 elicited comparable 
reductions of tumor growth. However, the dual drug administration reduced within-group 
variation, seen in tumor volume measurements throughout the experiment and downregulated 
tumor cell proliferation seen in tumor immunohistochemical analysis of Ki-67 positively 
stained cells. Surprisingly, in Daoy cell subcutaneous xenograft mice, GANT61 
administration did not reduce the tumor growth or Hedgehog signaling gene expression. 
Detailed qPCR and RNA-seq expression analysis of the individual R36 cell xenograft tumors 
indicated significant Hedgehog signaling downregulation in the RITA treatment group, 
minimal downregulation in the GANT61 treatment group and no downregulation in the 
combination group, suggesting a certain antagonism of the two drugs in vivo. 
3.2 PAPER II 
Blockade of the Hedgehog pathway downregulates estrogen receptor alpha signaling in 
breast cancer cells 
Anti-estrogen treatment, exemplified by tamoxifen, is a well-established therapy for ER-
alpha positive breast cancer, however development of drug resistance critically limits the 
effectiveness of the treatment. 
Expression of the key markers of Hedgehog signaling activity, i.e. GLI1 and PTCH1 was 
higher in tamoxifen resistant LCC2 cells than in parental tamoxifen sensitive MCF7 cells. 
Noteworthy, ER-alpha target genes ADORA1 and pS2 were upregulated in tamoxifen 
resistant cells, despite the comparable ER-alpha mRNA and protein expression. These 
suggests that in tamoxifen resistant cells higher Hedgehog signaling activity correlates with 
high ER-alpha activity. 
siRNA depletion of GLI1 decreased ER-alpha expression levels and cell proliferation in both 
cell lines, although to a lesser extent than in the case of siRNA-mediated ER-alpha depletion. 
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These observations are in line with the significance of ER-alpha in breast cancer cells 
(Thomas and Gustafsson, 2011), but still indicate that GLI1 can modulate proliferation in 
tamoxifen sensitive and resistant cell lines. 
siRNA depletion of GLI1 reduced ER-alpha protein levels, with concomitant reduction of 
ER-alpha activity, assessed with Estrogen Response Element luciferase reporter assay in both 
tamoxifen resistant and sensitive cells and irrespective of estrogen presence, suggesting an 
interplay of GLI with ER-alpha signaling. 
To address the functional consequences of GLI1 and ER-alpha interplay, we demonstrated 
that in the context of ER-alpha activation with estrogen, GLI1 depletion elicited a consistent 
reduction in the mRNA expression of ER-alpha itself and its target genes ADORA1, IL20 and 
pS2, as well decreased ER-alpha binding at the promoter region of pS2 in chromatin 
immunoprecipitation assay. Likewise, GLI1 depletion decreased ER-alpha protein levels 
irrespective of estrogen. However, exogenous expression of GLI1 did not increase the mRNA 
and protein levels of ER-alpha, implying that although GLI1 may regulate ER-alpha 
transcriptional activity when ER-alpha signaling is on, the impact of GLI1 on ER-alpha is 
more complicated than a typical direct GLI1 target (for example PTCH1). Noteworthy, we 
were unsuccessful at detecting convincing GLI1 binding sites on ER-alpha gene (ERS1) 
promoter or possible direct GLI1/ER-alpha interactions in immunoprecipitation assays. 
To address possible therapeutic application of Hedgehog-GLI1 and ER-alpha interplay, we 
showed that inhibition of GLI with GANT61 could sensitize breast cancer cells to tamoxifen 
treatment. First, we demonstrated that GANT61 treatment can reduce MCF7 and LCC2 cell 
viability in a dose dependent manner. Furthermore, GANT61 co-administration with 
tamoxifen further suppressed the growth of MCF7 and LCC2 cells to administration of only 
tamoxifen, and this was irrespective of estrogen stimulation. 
Gene expression analysis revealed that GLI1 expression positively correlates with the 
expression of ER-alpha gene ESR1 and the ER-alpha target genes pS2 and GREB1 in a 
previously published dataset of breast cancer samples from 286 individuals (Wang et al., 
2005). Additionally, high GLI1 expression predicted worse distant metastasis-free survival in 
breast cancer patients with grade I ER-alpha positive breast cancer (Gyorffy et al., 2010). 
These findings suggest that the GLI1 may be a new candidate for therapeutic targeting and 
prognosis in ER-alpha positive breast cancer. 
Taken together, in this work we have demonstrated that tamoxifen cytotoxicity can be 
enhanced by blockade of the Hedgehog pathway, reflecting a crosstalk between ER-alpha and 
GLI1 signaling, both in tamoxifen resistant and sensitive breast cancer cells.  
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3.3 PAPER III 
Identification of novel GLI1 target genes and regulatory circuits in human cancer cells 
GLI1 is a transcription factor, terminal effector and activator of Hedgehog signaling, it acts as 
an oncogene and its upregulation directly correlates with Hedgehog signaling activity. Yet 
very little is known about the GLI1 target genes, apart from a few targets, including GLI1, 
PTCH1, PTCH2 and HHIP. The expression and activity of GLI1 as a transcription factor are 
regulated by both transcriptional and post-transcriptional modifications, increasing the 
functional diversity of GLI1 and affecting GLI1-dependent biological outcomes. One such 
modification is Adenosine to Inosine editing of the GLI1 mRNA at nucleotide 2179, leading 
to a change from Arginine to Glycine at position 701 of the GLI1 protein, which was shown 
to modulate the activity of GLI1 (Shimokawa et al., 2013). In this study we identified 
multiple new GLI1 and edited GLI1 (GLI-701) target genes using a combination of different 
genomic surveys and subjected them to in-depth validation in human cancer cell lines. 
Rhabdomyosarcoma Rh36 cells were transfected with siRNA targeting GLI1 or expression 
plasmids overexpressing GLI1 or GLI1-701G and subjected to single molecule Helicos 
RNA-seq. The analysis of overexpression/depletion RNA-seq datasets allowed the selection 
of putative target genes. Combining the upregulated genes with a Z score > 2 in the GLI1 and 
GLI1-701G overexpression datasets and the downregulated genes with a fold change > 1.2 in 
the GLI1 depletion dataset, resulted in a final list of 29 genes. Gene Ontology analysis of this 
29-gene list revealed multiple genes encoding for functions potentially involved in 
downstream effects of GLI1 signaling, justifying their further validation. Thus, five genes, 
PTCH1, FOXS1, SOSTDC1, PLAT and ENC1 were validated at least in 6 out of 7 
independent qPCR-assay-based tests performed on both rhabdomyosarcoma Rh36 and 
medulloblastoma Daoy cells, these were: GLI1 depletion, GLI1 and GLI1-701G 
overexpressions in Rh36 and Daoy cells, Smoothened agonist (SAG) treatment in Daoy cells. 
Both in Rh36 and Daoy cells, genes that were preferentially or exclusively regulated by GLI1 
and GLI-701G were observed. Two of these genes TMEM158 and DNMT3B were commonly 
regulated in the two cell lines, while the remaining three and six unique to Rh36 and Daoy 
respectively, highlighting context-specific effects of GLI1 editing. 
One of the most highly upregulated targets of GLI1, FOXS1, was found to engage in 
feedback mechanism that limits the GLI1 cellular effects. Here, first we knocked out GLI1 in 
the Hedgehog signaling-responsive Daoy cells using CRISPR/Cas9 technology, generating 
two different GLI1 defective subclones. Next, we activated Hedgehog signaling in these cells 
with administration of SAG. These experiments concluded that FOXS1 upregulation by SAG 
requires functional GLI1. On the other hand, FOXS1 siRNA depletion resulted in increased 
GLI1 and HHIP expression in both Daoy and Rh36 cellular contexts. FOXS1 depletion also 
promoted Daoy and Rh36 cellular proliferation, arguing that the increased expression of 
FOXS1, elicited by GLI1 upregulation, acts in a negative feedback constraining GLI1 
activity. 
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Luciferase reporter and immunoprecipitation assays suggested a potential mechanism on the 
interplay between FOXS1 and GLI1, as FOXS1 was found to interact with GLI1 and block 
GLI1 activity. 
Moreover, FOXS1 was both highly expressed and positively correlated with GLI1 in 
medulloblastoma samples of the SHH subgroup, based on a previously published dataset of a 
large medulloblastoma cohort of 392 samples (Downing et al., 2012) that included all four 
medulloblastoma subtypes. This further argues for the existence of FOXS1/GLI1 interplay in 
human tumors and its clinical relevance. Consistently, high FOXS1 expression predicted 
longer relapse-free survival in breast cancer in another previously published dataset (Lanczky 
et al., 2016). Consequently, FOXS1 may have tumor suppressive properties and its 
upregulation in tumors could be a marker of good prognosis. 
3.4 PAPER IV (Manuscript) 
Circular RNAs in Hedgehog signaling activation and Hedgehog-mediated 
medulloblastoma tumors 
There is overwhelming evidence that circRNAs are deregulated in increasing number of 
cancers (Vo et al., 2019). However, there is no comprehensive information on deregulated 
circRNAs in medulloblastoma and how this may impact the development of this cerebellar 
cancer. In this manuscript we addressed the role of circRNAs in the context of Hedgehog 
signaling activation and Hedgehog-linked medulloblastoma tumors. 
We have characterized the circRNA transcriptome of two Hedgehog signaling inducible cell 
lines, medulloblastoma Daoy and non-cancerous HEPM (human embryonic palatal 
mesenchyme) cells in the context of Hedgehog signaling activation. This has been achieved 
by administration of purified SHH ligand or the small molecule SAG, an agonist of SMO co-
receptor, and the subsequent upregulation of the key markers of Hedgehog signaling activity, 
GLI1 and HHIP was assessed in qPCR assays. Next, total RNA from treated and untreated 
cells was divided into two fractions to enrich for either linear mRNAs (poly(A) selection) or 
circRNAs (ribosomal RNA depletion and RNase R treatment), and subjected to Illumina 
RNA-seq. Specific bioinformatical pipelines (CIRCexplorer2/TopHatFusion) were 
implemented to identify circRNA reads generated by back-splicing of exons (Zhang et al., 
2016), the marker of exonic RNA circles. 
RNA-seq analysis of the mRNA fraction confirmed the Hedgehog pathway upregulation seen 
in qPCR assays, as the key markers of Hedgehog pathway activation, GLI1, HHIP, PTCH1 
were among the most upregulated genes upon SHH/SAG treatments in both Daoy and HEPM 
cellular contexts. 
RNA-seq analysis of the circRNA fraction resulted in a list of 29 abundantly expressed 
circRNAs, which were independently validated by Sanger sequencing and in PCR assays, 
using divergent primers detecting the back-spliced junction of the RNA circle. 10 of these 
circRNAs were the top most abundantly expressed in Daoy and HEPM cells, 10 the most 
 24 
abundant and differentially expressed in SAG/SHH treatments of Daoy and HEPM cells, 3 
abundant circRNAs derived from genes involved in Hedgehog signaling, and 6 circRNAs 
from the top 50 in Daoy medulloblastoma cells that were differentially expressed in normal 
cerebellum, based on publicly available circBase database (www.circbase.org, (Rybak-Wolf 
et al., 2015)). 
Interesting to note, all but one of the 10 circRNAs apparently differentially expressed in Daoy 
or HEPM RNA-seq datasets were downregulated in the context of Hedgehog signaling 
activation. To our surprise, the qPCR analysis of the differentially expressed circRNAs did 
not show consistent differences in the expression compared to control. This might be due to 
the small expression differences (2-fold or 1.5 fold) of circRNA transcripts in the RNA-seq 
data and the relative stability (24-48 hr half-life) of circRNAs, which would make difficult 
the detection of changes within the 48-72 hr timeframe of SAG/SHH treatments. In fact, this 
provides a possible explanation as to why fewer differentially expressed circRNAs were 
detected compared to differentially expressed mRNAs (Enuka et al., 2016). Notably, in both 
cellular contexts, the expression of circRNAs was lower than that of mRNAs originating 
from the same parental gene, with no correlation detected between circular and concordant 
linear reads. This is consistent with a previous study (Vo et al., 2019) and indicative of 
distinct mechanisms involved in back-splicing compared to forward-splicing. 
Next, we independently validated the 29 circRNAs in two medulloblastoma cell lines (Daoy, 
UW-228), SHH-medulloblastoma tumor sample, and compared the expression of these 
circRNAs to that in normal cerebellum (three independent cerebellar samples, from 5 
different individuals). Again, most of the circRNAs were significantly downregulated in 
medulloblastoma in comparison to cerebellum, with none being upregulated and consistent 
with previous studies, as circRNAs appear to be preferentially downregulated in cancers 
(Bachmayr-Heyda et al., 2015), including medulloblastoma (Lv et al., 2018). The correlation 
of expression in cerebellum and in medulloblastoma of several circRNAs with their 
corresponding linear counterparts was particularly low. Specifically, the BACH1, CDYL, 
FKBP8, GLIS1, OGDH, SMARCA5 and ZKSCAN1 circRNA expression was significantly 
downregulated in medulloblastoma versus cerebellum, while the expression of their linear 
counterparts was unchanged. This indicates that these circRNAs are products of differently 
regulated splicing events and distinct mechanisms are involved in their expression, which 
would be consistent with a possible functional impact. 
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4 General discussion and future perspectives 
Hedgehog signaling is vital for diverse aspects of animal development and essential in 
regulating many cellular processes, including tumorigenesis. Notably, the role of the GLI1 
transcription factor is crucial in regulating Hedgehog pathway activity, as it acts as a target 
gene, terminal effector, signal amplifier and a direct marker of the pathway activity. 
Cancer is a heterogeneous disease and numerous factors and signaling pathways are involved 
in its initiation and progression. Thus, therapeutic approaches aiming at controlling a single 
aspect of tumor development are unlikely to result in a sustained effect. Sporadic mutations, 
development of resistance and side effects are common complications urging for novel 
treatment strategies. Identification and context-specific targeting of new target genes, 
feedback mechanisms and interactors that may affect signaling activity in Hedgehog-
mediated tumors are of relevance. 
In PAPER III, we identified numerous targets of GLI1, whose potential mechanistic roles in 
Hedgehog-GLI1 activation are worth further studying. We found that FOXS1, a gene 
encoding a transcription factor previously implicated in nervous system development 
(Montelius et al., 2007) is involved in negative feedback loop, limiting the GLI1 cellular 
effects. It is possible that a high FOXS1 to GLI1 ratio rather than just high FOXS1 levels can 
better predict a positive outcome in GLI1-dependent tumors, and we show such correlation 
for SHH group medulloblastomas, prostate and breast cancers. Remarkably, FOXS1 was 
upregulated more than 3-fold in the Daoy medulloblastoma cell line upon Hedgehog 
signaling activation with SHH ligand (Paper IV), while two additional prominent targets, 
SOSTDC1 and SOX18 were upregulated in HEPM cells. The functional role of the 
FOXS1/GLI1 regulatory loop in vivo can be further studied in existing mouse models with 
inactivated FOXS1 (Foxs1+/ß-gal mice, (Heglind et al., 2005)) and GLI-Luciferase transgenic 
mice with overactivated and traceable GLI1 (Kimura et al., 2008). 
In PAPER I, while aiming at investigating the potential inhibitory role of p53 activation on 
Hedgehog signaling, we came across novel Hedgehog-inhibitory properties of RITA that 
occur irrespective of p53. These inhibitory functions of RITA could be studied in additional 
cancer cell contexts other than medulloblastoma and rhabdomyosarcoma. It would be 
interesting to investigate whether RITA can directly bind to GLI1/2, for example in cellular 
thermal shift assays (CETSA) and whether a competition between RITA and GANT61 exist 
for binding to GLI1/2 proteins. Furthermore, to address (or rule out) the possibility of 
unspecific DNA damage response of the cells to RITA, we could perform additional Western 
blot analysis in Daoy and Rh36 cells and follow changes in protein levels of DNA damage 
markers, such as PARP, gamma-H2AX upon RITA treatment and compare those effect with 
known DNA damaging agents, i.e. Doxorubicin and Oxaliplatin. 
In PAPER II, we have shown that GLI1 can be a potential therapeutic target and a diagnostic 
marker in breast cancer. Moreover, in combinatorial treatments the GLI antagonist GANT61 
could further sensitize breast cancer cells to tamoxifen treatment. This could be worth 
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examining in animal xenograft models, as apparently, in vivo synergistic/additive effects of 
drug combinations might not fully reflect the in vitro scenarios. Especially, since such a 
variability occurred with GANT61 and RITA co-treatments in PAPER I. Next, since we have 
shown that GLI1 depletion can downregulate expression and transcriptional activity of ER-
alpha, reduce ER-alpha recruitment on the promoter of its target gene pS2, further efforts to 
investigate a possible GLI1-ER-alpha interaction would be of relevance. Particularly, such 
interaction can be studied in chromatin immunoprecipitation assays following GLI1 
overexpression via the adenoviral system used in Paper III. 
In PAPER IV, we have addressed the role of a new class of biomolecules, circRNAs, in the 
context of Hedgehog activation and Hedgehog-linked medulloblastoma. The vast majority of 
human transcripts represent non-coding sequences and advances of transcriptome sequencing 
made it possible to study numerous novel classes of RNAs, including circRNAs. Given the 
increasing body of evidence linking circRNAs expression with human biology, e.g. cancer 
development and brain function, we aim to extensively address the circRNAs role in 
medulloblastoma development, with a primary focus on the SHH subtype of 
medulloblastomas. 
In this manuscript, we generated a candidate list of abundantly and/or differentially expressed 
circRNAs that were first identified in RNA-seq datasets of Hedgehog-inducible human cell 
lines (Daoy medulloblastoma and HEPM non-cancerous cells) and then independently 
validated these circRNAs by Sanger sequencing, PCR and qPCR assays in SHH subtype 
medulloblastoma cells (Daoy, UW-228), SHH medulloblastoma tumor and normal 
cerebellum samples. Currently, we are functionally addressing the impact of these circRNAs 
on cellular growth in vitro via depletion/overexpression experiments in Daoy and UW-228 
cells. This is achieved by designing siRNAs that target the back-sliced junction, which is 
present in circRNAs, but absent in the corresponding linear mRNAs. Moreover, circRNAs 
will be overexpressed using commercially available specialized expression vectors (Barrett 
and Salzman, 2016). Afterwards, ex vivo xenografts could be used to address the effects of 
circRNA depletion/overexpression in the context of a growing tumor (Villegas et al., 2014). 
Additionally, it is possible to further study the mechanism of selected circRNAs action by 
identifying these circRNAs interactors. Protein-circRNA and nucleic acids-circRNA 
interactions can be studied using the recently developed techniques for circRNA precipitation 
(Han et al., 2017) and chromatin isolation by RNA purification (Chu and Chang, 2018). 
Moreover, potential miRNAs that can interact with selected circRNAs can be identified using 
bioinformatic analysis and later validated by biochemical methods. 
Next, prompted by the above data (PAPER IV, manuscript), which suggests that circRNAs 
may indeed be deregulated in medulloblastoma, we have already planned to engage in a more 
comprehensive analysis of circRNAs using a large collection of human tissue samples. Here, 
an expanded list of circRNAs that are differentially expressed in medulloblastomas versus 
normal cerebellum will be identified. In fact, we already have generated RNA-seq data of 6 
medulloblastoma tumors (of which at least 3 are SHH medulloblastomas) and 3 normal 
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cerebellum samples. Moreover, we are in the final stage of receiving a large number of 
additional human medulloblastoma samples of the SHH subgroup, four of which are 
progressive tumors. 
Assuming that these analyses result in a robust list of deregulated circRNAs, we plan to 
extend our efforts to the other three medulloblastoma subgroups, i.e. WNT, group 3 and 
group 4. It is anticipated that such analysis will pinpoint the similarities and the differences in 
circRNA expression during the development of all medulloblastoma subgroups, possibly 
providing a basis for targeted approaches aiming at constraining the growth of this cerebellar 
tumor. 
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